|Bid||26.87 x 0|
|Ask||27.00 x 0|
|Day's Range||26.24 - 27.38|
|52 Week Range||11.20 - 30.56|
|PE Ratio (TTM)||6.87|
|Earnings Date||Feb 26, 2018 - Mar 2, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||19.71|
Valeant Pharmaceuticals International Inc (NYSE:VRX) is trading with a trailing P/E of 5.6x, which is lower than the industry average of 24.2x. Although some investors may jump to the conclusionRead More...
RBC Capital analysts argue Allergan could raise around $1 billion and send a "strong signal" on profitability with the sale of its anti-infectives business.
Bill Ackman’s $290 million settlement agreement with shareholders of drug developer Allergan plc has the support of a California federal judge. This is good news for the New York-based activist investor and Valeant Pharmaceuticals, as the two parties are being sued for insider trading. “The Court has vacated the trial date and indicated its preliminary approval of the settlement subject to submission of final papers and associated hearings,” Valeant said in a statement.
LONDON, UK / ACCESSWIRE / January 17, 2018 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Drug Manufacturers industry: Valeant Pharmaceuticals ...
A federal judge signaled he would approve a $290 million settlement reached by Pershing Square, Valeant and the shareholders of Allergan who had alleged the two firms improperly profited from their failed ...
Shares of Valeant Pharmaceuticals International (VRX) have more than doubled the S&P 500's return during the past 12 months. H.C. Wainwright's Raghuram Selvaraju is warming to the stock. Valeant has made "significant strides" in moving its pipeline forward in recent months, he writes, while also making "substantial progress" on its debt.
Shares of Valeant Pharmaceuticals International (VRX) are higher on Friday, following acceptance of the application of one of its subsidiaries' acne medications. Valeant said that the Food and Drug Administration approved its New Drug Application for its tretinoin acne lotion, with an approval date of August 27, 2018.
PDUFA Date Is Aug. 27, 2018 LAVAL, Quebec , Jan. 12, 2018 /PRNewswire/ -- Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") , ...
Activist investor Bill Ackman said he would slash the 1.5 percent annual management fee for his hedge fund Pershing Square Holdings Ltd. According to a letter posted to the Pershing Square (PSHZF) website, Ackman says he will be reducing future management fees for all of the funds which incurred recent litigation expenses by a total of $32.2 million. The litigation referenced in the letter pertains to Ackman and Valeant Pharmaceuticals' settling a long-standing dispute against drug developer Allergan plc.
Valeant Pharmaceuticals International Inc. became a household name with its historic rise and fall. Reviving the drugmaker is proving a unique challenge.
With the stock of the drugmaker hovering around $23 a share and its reputation bloodied, CEO Joe Papa tried to explain his company's comeback efforts to investors.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting VRX. Over the last month, growth of ETFs holding VRX is favorable, with net inflows of $4.45 billion.
Seven Key Products Are Projected to Generate $1 Billion in Sales in 5 Years LAVAL, Quebec , Jan. 9, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant" ...
With the buyback of Sprout Pharmaceuticals and its female libido drug Addyi from Valeant Pharmaceuticals (VRX) last month, some 203 legacy Sprout shareholders have swapped their stakes for ones in Sprout2 Inc. – a Raleigh-based company affiliated with former Sprout shareholders , including former Sprout CEO Cindy Whitehead. Listed in the filing as executive officers and directors of Sprout2 are Cindy Whitehead and Robert Whitehead, who co-founded Sprout prior to its $1 billion acquisition by Valeant back in 2015.
In 3Q17, Valeant's (VRX) Arestin reported revenues of $26 million, which was ~7% lower on a YoY (year-over-year) basis and 7% lower quarter-over-quarter.
In 3Q17, Valeant’s Xifaxan reported revenues of $286 million, which was ~5% higher on a YoY (year-over-year) basis and a 23% rise quarter-over-quarter.
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) announced this morning that its subsidiary Bausch + Lomb has received CE Mark from the European Commission for the Stellaris Elite™ Vision Enhancement System, the company's next generation ophthalmic surgical platform, which includes Vitesse™, the first and only hypersonic, open-port vitrectomy system. The Stellaris Elite platform is now available throughout greater Europe, including the 28 countries of the European Union, Iceland, Liechtenstein, Norway and Switzerland. "We're pleased to bring the Stellaris Elite Vision Enhancement System, including the cutting-edge Vitesse technology, to the greater European market," said Joseph C. Papa, chairman and CEO, Valeant.
Next-Generation Ophthalmic Surgical Platform Now Available Across Greater Europe LAVAL, Quebec , Jan. 8, 2018 /PRNewswire/ -- Bausch + Lomb, a leading global eye health company and wholly owned subsidiary ...
In 3Q17, Valeant Pharmaceuticals’ (VRX) branded prescription drugs generated revenues of ~$633 million, compared with $766 million in 3Q16.
In 3Q17, Valeant Pharmaceuticals’ Bausch + Lomb’s Soflens generated revenues of $83 million, which was ~5% higher on a YoY basis and ~9% higher QoQ.
At the J.P. Morgan Health Care Conference, Valeant CEO Joe Papa speaks with CNBC's Meg Tirrell about the turnaround in the company and their drug pricing strategy.